Select a medication above to begin.
Elevidys (delandistrogene moxeparvovec-rokl)
delandistrogene moxeparvovec
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = delandistrogene moxeparvovec-rokl
Duchenne muscular dystrophy
- [10-70 kg]
- Dose: 1.33 x10^14 vector genomes/kg/dose IV x1; Info: for ambulatory or non-ambulatory pts w/ confirmed mutation in DMD gene and anti-AAVrh74 total binding antibody titer <1:400; use w/ corticosteroid, see pkg insert for dose
- [>70 kg]
- Dose: 9.31 x10^15 vector genomes IV x1; Info: for ambulatory or non-ambulatory pts w/ confirmed mutation in DMD gene and anti-AAVrh74 total binding antibody titer <1:400; use w/ corticosteroid, see pkg insert for dose
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- hepatic impairment/chronic hepatic dz: not defined, caution advised; acute hepatic dz: avoid use
Peds Dosing .
- Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = delandistrogene moxeparvovec-rokl
Duchenne muscular dystrophy
- [4 yo and older, 10-70 kg]
- Dose: 1.33 x10^14 vector genomes/kg/dose IV x1; Info: for ambulatory or non-ambulatory pts w/ confirmed mutation in DMD gene and anti-AAVrh74 total binding antibody titer <1:400; use w/ corticosteroid, see pkg insert for dose
- [4 yo and older, >70 kg]
- Dose: 9.31 x10^15 vector genomes IV x1; Info: for ambulatory or non-ambulatory pts w/ confirmed mutation in DMD gene and anti-AAVrh74 total binding antibody titer <1:400; use w/ corticosteroid, see pkg insert for dose
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- hepatic impairment/chronic hepatic dz: not defined, caution advised; acute hepatic dz: avoid use
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- infection, active
- hepatic dz, acute
- anti-AAVrh74 total binding antibody titer >1:400
- DMD gene w/ exon 8-9 deletion
- caution: DMD gene w/ exon 1-7 deletion
- caution: DMD gene w/ exon 10-17 deletion
- caution: DMD gene w/ exon 59-71 deletion
- caution: hepatic impairment
- caution: hepatic dz, chronic
- caution: LVEF impairment
Drug Interactions .
Overview
delandistrogene moxeparvovec
gene therapy
-
None
No significant interactions known or found for this drug. Caution always advised with multiple medications.
Adverse Reactions .
Serious Reactions
- hepatic injury, acute
- immune-mediated myositis
- myocarditis
- infusion rxn, severe
- anaphylaxis
Common Reactions
- vomiting
- nausea
- LFTs incr.
- fever
- thrombocytopenia
Safety/Monitoring .
Monitoring Parameters
LFTs at baseline, then qwk x3mo; Plt at baseline, then qwk x2wk; troponin-I at baseline, then qwk x1mo; s/sx infusion rxn during and for at least 3h after infusion
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; no human or animal data available
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: proteolytic degradation (protein capsid); CYP450: none
Excretion: urine, feces; Half-life: 12h (serum), 40h (urine), 55h (feces), 60h (saliva)
Subclass: Muscular Dystrophies
Mechanism of Action
recombinant adeno-assoc. viral vector delivers gene encoding a micro-dystrophin protein to target muscle cells
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.